4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...
expected growth as well as a full year of contribution from both Verona’s Ohtuvayre and Merck’s Capvaxive. Captisol sales are expected to rise over 30% to $35 to $40 million, propelled by an ...
U.K. researchers at Nottingham Trent University, the University of Southampton and University Hospital Southampton and product development company Zelemiq Ltd. developed a wearable sensor that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback